查看購物車
  • Simplified Chinese
  • English
2030 年中東和非洲傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路
市場調查報告書
商品編碼
1562243

2030 年中東和非洲傳染病治療市場預測 - 區域分析 - 按藥物類別、適應症、給藥途徑和配銷通路

Middle East & Africa Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route of Administration, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 93 Pages | 訂單完成後即時交付

價格

2022年中東和非洲傳染病治療市場價值為57.2281億美元，預計到2030年將達到72.3761億美元；預計2022年至2030年複合年成長率為3.0%。

傳染病發生率上升推動中東和非洲傳染病治療市場

傳染病是由病毒、寄生蟲、細菌、真菌、有毒產物和其他傳染源引起的。愛滋病毒是全世界的重大公共衛生議題。根據聯合國愛滋病毒/愛滋病聯合規劃署 (UNAIDS) 的數據，2020 年，約有 3,770 萬人感染愛滋病毒。其中，3600萬是成年人，170萬是0-14歲的兒童。此外，超過一半（53%）是女孩和婦女。此外，2020 年全球報告了 150 萬新的愛滋病毒病例。同樣，肝炎是由病毒感染引起的肝臟感染。肝炎病毒的主要類型為甲型、乙型、丙型、丁型和戊型 根據世界衛生組織(WHO) 統計，全球約有5,800 萬人患有慢性丙型肝炎病毒感染，每年約有150 萬人患有慢性丙型肝炎病毒感染。

據世界衛生組織稱，結核病 (TB) 是全球第 13 大死亡原因，也是僅次於 COVID-19 的第二大傳染病。 2020 年，結核病導致 150 萬人死亡（其中 214,000 人感染愛滋病毒）。此外，2020年全球有1,000萬人患有結核病，其中包括110萬名兒童、330萬名女性和560萬男性。此外，院內感染或醫療保健相關感染（HAI）的發生率和死亡率很高。此外，每年醫療保健系統的支出也是巨大的。因此，全球傳染病率的上升推動了傳染病治療市場的成長。

中東和非洲傳染病治療市場概述

中東和非洲的傳染病治療市場包括對阿拉伯聯合大公國、沙烏地阿拉伯、南非以及中東和非洲其他地區的國家級分析。市場的成長可歸因於慢性病毒性疾病的流行以及該地區不斷成長的研究。此外，先進醫療設施的出現可能會在預測期內推動市場成長。由於龐大的人口基數和日益流行的傳染病，沙烏地阿拉伯是中東和非洲成長最快的地區之一。沙烏地阿拉伯的結核病是透過移民工人和朝聖者傳播。根據世界資料圖譜，沙烏地阿拉伯的結核病發生率從2002年的每10萬人17例逐漸下降到2021年的每10萬人8例。 ），在沙烏地阿拉伯，控制血液和呼吸道非常具有挑戰性。據世界衛生組織稱，流感和肺炎死亡人數佔全國總死亡人數的4.58%。為了應對不斷成長的流感病例，沙烏地阿拉伯公共衛生實驗室滿足了世界衛生組織被認可為沙烏地阿拉伯國家流感中心的所有要求。該中心在快速檢測和監測傳染病方面發揮關鍵作用。 NIAID 積極參與該地區傳染性病毒疾病的研究，包括中東呼吸道症候群冠狀病毒 (MERS-CoV)。 MERS-CoV 是一種新發現的冠狀病毒，已傳播到該地區至少九個國家。 NIAID 積極參與該地區傳染性病毒性疾病的研究。同樣，該地區的產品推出也在增加，並對患者的生活品質產生積極影響。因此，預計越來越多的病毒性疾病和產品上市將推動該國傳染病治療的成長。

中東和非洲傳染病治療市場收入及 2030 年預測（百萬美元）

中東和非洲傳染病治療市場細分

中東和非洲傳染病治療市場按藥物類別、適應症、給藥途徑、配銷通路和國家分類。

依藥物類別，中東和非洲傳染病治療市場分為抗病毒、抗菌、抗真菌等。 2022 年，抗病毒藥物領域佔據最大的市場佔有率。

從適應症來看，中東和非洲傳染病治療市場分為愛滋病毒、肝炎、結核病、流感、HPV等。 2022 年，HIV 佔據最大的市場佔有率。

根據給藥途徑，中東和非洲傳染病治療市場分為口服、腸胃外、外用等。 2022 年，口腔細分市場佔據最大的市場佔有率。

從配銷通路來看，中東和非洲傳染病治療市場分為醫院藥局、零售藥局等。 2022年，醫院藥局佔最大的市場佔有率。

按國家/地區分類，中東和非洲傳染病治療市場分為沙烏地阿拉伯、南非、阿拉伯聯合大公國以及中東和非洲其他地區。 2022 年，沙烏地阿拉伯在中東和非洲傳染病治療市場佔有率中佔據主導地位。

艾伯維公司、安斯泰來製藥公司、拜耳公司、羅氏公司、吉利德科學公司、葛蘭素史克公司、默克公司和輝瑞公司是中東和非洲傳染病治療市場上的一些領導公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：中東和非洲傳染病治療市場 - 主要市場動態

  • 中東和非洲傳染病治療市場 - 主要市場動態
  • 市場促進因素
    • 傳染病病率上升
    • 越來越關注傳染病治療的經費與研發
  • 市場限制
    • 抗感染藥物抗藥性的出現及相關副作用
  • 市場機會
    • 抗生素抗藥性威脅不斷升級
  • 未來趨勢
    • 產品批准和發布數量不斷增加
  • 促進因素和限制的影響：

第 5 章：傳染病治療市場 - 中東和非洲市場分析

  • 中東和非洲傳染病治療市場收入，2022-2030

第 6 章：中東和非洲傳染病治療市場分析 - 按藥物類別

  • 概述
  • 抗病毒劑
  • 抗菌
  • 抗真菌
  • 其他

第 7 章：中東和非洲傳染病治療市場分析 - 按適應症

  • 概述
  • 愛滋病
  • 肝炎
  • 結核
  • 流感
  • HPV病毒
  • 其他

第 8 章：中東和非洲傳染病治療市場分析 - 按給藥途徑

  • 概述
  • 口服
  • 注射用
  • 專題
  • 其他

第 9 章：中東和非洲傳染病治療市場分析 - 按配銷通路

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 10 章：中東和非洲傳染病治療市場 - 國家分析

  • 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：傳染病治療市場-產業格局

  • 概述
  • 傳染病治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 12 章：公司簡介

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第 13 章：附錄

Product Code: BMIRE00030459

The Middle East & Africa infectious disease therapeutics market was valued at US$ 5,722.81 million in 2022 and is expected to reach US$ 7,237.61 million by 2030; it is estimated to register a CAGR of 3.0% from 2022 to 2030.

Rising Prevalence of Infectious Disease Fuels Middle East & Africa Infectious Disease Therapeutics Market

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.

Middle East & Africa Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in the Middle East & Africa includes a country-level analysis of the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth can be attributed to the increasing prevalence of chronic viral diseases and growing research studies across the region. Moreover, the emergence of advanced healthcare facilities is likely to propel market growth during the forecast period. Saudi Arabia is among the fastest-growing regions in the Middle East & Africa, driven by a huge population base and the increasing prevalence of infectious diseases. Tuberculosis in Saudi Arabia is spread through migrant workers and pilgrims. According to the World Data Atlas, the incidence rate of tuberculosis in Saudi Arabia gradually fell from 17 cases per 100,000 people in 2002 to 8 cases per 100,000 people in 2021. Further, K. pneumoniae, a hospital-acquired infection of the urinary tract, bloodstream, and respiratory tract, is very challenging to control in Saudi Arabia. Influenza and pneumonia deaths reached 4.58% of total deaths in the country, according to WHO. To address the growing influenza cases, the Public Health Laboratory in Saudi Arabia fulfilled all the requirements by WHO to be recognized as a national influenza center for Saudi Arabia. The center plays a critical role in rapidly detecting and monitoring infectious diseases. NIAID is significantly involved in research on infectious viral diseases in the region, including MERS-CoV. MERS-CoV, a newly identified coronavirus, has spread to at least nine countries in the region. NIAID is significantly involved in research on infectious viral diseases in the region. Similarly, product launches in the region are increasing and are positively impacting patients' quality of life. Thus, the growing number of viral diseases and product launches is anticipated to propel the growth of infectious disease therapeutics in the country.

Middle East & Africa Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Infectious Disease Therapeutics Market Segmentation

The Middle East & Africa infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Middle East & Africa infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Middle East & Africa infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Middle East & Africa infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Middle East & Africa infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Middle East & Africa infectious disease therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the Middle East & Africa infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Middle East & Africa Market Analysis

  • 5.1 Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Middle East & Africa Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 Middle East & Africa Infectious Disease Therapeutics Market
    • 10.1.1 Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 South Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 South Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 South Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 South Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.7.4 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.8 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.8.1 Overview
      • 10.1.1.9 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.9.1 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.9.2 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.9.3 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.9.4 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Bayer AG
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 GSK Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 AbbVie Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Merck & Co Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Astellas Pharma Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners

List Of Tables

  • Table 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation
  • Table 2. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 3. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 4. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 5. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 6. Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 7. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 8. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 9. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 10. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 11. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 12. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 13. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 14. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 15. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 16. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 17. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 19. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 20. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 21. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 22. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 23. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 24. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Middle East & Africa Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Growth Strategies in the Infectious Disease Therapeutics Market